SIETES :: 91904 citas

Resultados de la búsqueda por DNID REFINAR BÚSQUEDA

1.

Anónimo. Actualización de insulinas. Infac: Información Farmacoterapéutica de la Comarca 2017;25:1-10. [Ref.ID 101631]

2.

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 2017;357:j2499. [Ref.ID 101630]

3.

Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2. [Ref.ID 101628]

4.

Anónimo. EMA’s CHMP recommends approval of biosimilar insulin lispro. DIA Daily 2017:2. [Ref.ID 101598]

5.

Hu Y-m, Zhou F, Yuan Y, Xu Y-c. Efectos del suplemento de probióticos en pacientes con diabetes tipus 2: mataanálisis de ensayos aleatorizados. Med Clin (Barc) 2017;148:362-70. [Ref.ID 101575]

6.

Greenway T, Ross JS. US drug marketing: how does promotion correspond with health value?. BMJ 2017;357:j1855. [Ref.ID 101571]

7.

Gorricho J, Garjón J, Alonso A, Celaya MC, Saiz LC, Erviti J, López A. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin Pharmacol 2017:11 de marzo. [Ref.ID 101545]

8.

Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2017;40:468-75. [Ref.ID 101507]

9.

Flory J. Will cardiovascular outcomes data on newer diabetes drugs bury the older agents?. JAMA Intern Med 2017;177:301-2. [Ref.ID 101462]

10.

Anónimo. Lixisenatide for type 2 diabetes. Med Lett Drugs Ther 2017;59:19-21. [Ref.ID 101420]

11.

Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]

12.

Anónimo. Drugs for type 2 diabetes. Med Lett Drugs Ther 2017;59:9-18. [Ref.ID 101372]

13.

Saiz Fernández LC. Ensayo EMPA-REG OUTCOME (empagliflozina) El poder de la verdad, la verdad del poder.. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-13. [Ref.ID 101347]

14.

Anónimo. An update on the "gliptins". Drug Ther Bull 2016;54:138-41. [Ref.ID 101014]

15.

Anónimo. Pioglitazone-containing medicines: Drug safety communication - Updated FDA review, increased risk of bladder cancer. FDA MedWatch alert 2016:12 diciembre. [Ref.ID 100996]

16.

Anónimo. Juno suspends clinical trial after two additional patient deaths. DIA Daily 2016:4. [Ref.ID 100980]

17.

Anónimo. FDA approves diabetes drug. DIA Daily 2016:2. [Ref.ID 100975]

18.

Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, Inzucchi SE, Gill TM, Krumholz HM, Shah ND. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care 2016:septiembre. [Ref.ID 100915]

19.

Anónimo. Capsaïcine et douleurs neuropathiques diabétiques. Prescrire 2016;36:734-6. [Ref.ID 100890]

20.

Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]